A randomized, double-blind placebo-controlled trial recently published in the Lancet explored the use of gabapentin for the treatment of refractory chronic cough (> 8 weeks’ duration). Sixty- two participants without active respiratory disease or infection were assigned to either gabapentin (maximum tolerable daily dose of 1800 mg) or placebo for 10 weeks. Based on the findings of the study, gabapentin significantly improved cough-specific quality of life compared to placebo and had minimal side effects that were easily controlled by dose reduction. What do you routinely recommend for patients with refractory chronic cough?
For more information, please visit sciencedirect.com